Boston Scientific Buys Venous Stent-Developer Veniti For $160M

Boston Scientific has agreed to pay up to $160m for the remaining 75% of Veniti Inc. that it does not already own. Veniti is a privately held Fremont, Calif. company that has developed and commercialized the Vici venous stent system for treating venous obstructive disease. The transaction price includes $108m upfront and $52m contingent on US FDA approval of Vici.